Quick verdict
9amHealth is the better pick for most patients on overall scoring. 9amHealth treats GLP-1 as one tool inside a broader cardiometabolic program. Strong employer and insurance relationships, branded-first medication strategy, labs included. Best fit for patients with comorbidities, not pure weight-loss buyers.
That said, Embla wins on specific dimensions. Embla is the closest thing the US market has to a Noom-meets-Calibrate hybrid that actually leans into the medication. Heavy behavioral coaching, branded-first prescribing, structured 12-month curriculum. Best for buyers who want the program to do half the work.
Side-by-side
| 9amHealth | Embla | |
|---|---|---|
| Starts from | $25/mo (+ med separate) | $249/mo (+ med separate) |
| Lock-in | Month-to-month | 12-month commitment |
| Time to prescription | 5 days | 7 days |
| Consultation type | Synchronous | Synchronous |
| Affiliate network | Direct | Impact |
Score by dimension
Five dimensions, ten points each. The winner of each dimension is highlighted.
| 9amHealth | Embla | |
|---|---|---|
| Pricing transparency | 7/10 | 6/10 |
| Cancellation terms | 8/10 | 7/10 |
| Onboarding experience | 6/10 | 6/10 |
| Medication options | 7/10 | 7/10 |
| Member outcomes | 8/10 | 8/10 |
When to choose 9amHealth
Patients with diabetes, prediabetes, or cardiovascular risk who want GLP-1 inside comprehensive metabolic care.
When to choose Embla
Patients who tried meds-only and bounced, and want a structured behavior program alongside GLP-1.
FAQ
Is 9amHealth cheaper than Embla?
Can I switch from 9amHealth to Embla mid-treatment?
Which program has better member feedback?
Read the full reviews
All head-to-head comparisons → · Full chart →